Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chlorambucil
Drug ID BADD_D00429
Description A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Indications and Usage For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
Marketing Status Prescription
ATC Code L01AA02
DrugBank ID DB00291
KEGG ID D00266
MeSH ID D002699
PubChem ID 2708
TTD Drug ID D0V8QT
NDC Product Code 71052-212; 76055-0025; 76388-635; 72969-010; 50683-0384; 49452-1911; 43744-066
Synonyms Chlorambucil | 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid | N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid | Chloraminophene | Chlorbutin | NSC-3088 | NSC 3088 | NSC3088 | Leukeran | Lympholysin | Amboclorin | CB-1348 | CB 1348 | CB1348
Chemical Information
Molecular Formula C14H19Cl2NO2
CAS Registry Number 305-03-3
SMILES C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Stevens-Johnson syndrome10.01.03.020; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Stomatitis07.05.06.005--
Supraventricular tachycardia02.03.03.0120.000533%
Swelling face23.04.01.018; 10.01.05.0180.000533%Not Available
Syncope02.01.02.008; 24.06.02.012; 17.02.04.0080.001066%
Tachycardia02.03.02.0070.001332%Not Available
Testicular atrophy21.13.01.001; 05.05.02.004--Not Available
Thrombocytopenia01.08.01.0020.004529%Not Available
Toxic epidermal necrolysis11.07.01.006; 10.01.01.006; 23.03.01.008; 12.03.01.015--
Tremor17.01.06.0020.000533%
Tumour lysis syndrome16.32.03.002; 14.05.01.0040.002398%
Ureteric obstruction20.06.01.005--Not Available
Urinary tract infection20.08.02.001; 11.01.14.0040.002131%
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.0030.001332%
Weight decreased13.15.01.0050.001332%
White blood cell count decreased13.01.06.0120.002664%
Neutropenic sepsis01.02.03.007; 11.01.11.0060.000208%Not Available
Cytokine release syndrome10.02.01.0100.000139%
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.001--Not Available
Enterobacter sepsis11.02.09.0010.000533%Not Available
Transaminases increased13.03.01.0150.001332%Not Available
Blood alkaline phosphatase increased13.04.02.0040.000533%
Urine output13.13.03.003--Not Available
Metastatic neoplasm16.16.01.007--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Respiratory tract infection22.07.07.001; 11.01.08.0170.001066%Not Available
Cystitis noninfective20.03.02.001--
Bone marrow failure01.03.03.005--
Cytopenia01.03.03.0120.000799%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages